000154497 001__ 154497
000154497 005__ 20240229123104.0
000154497 0247_ $$2doi$$a10.1088/1361-6560/ab8955
000154497 0247_ $$2pmid$$apmid:32294637
000154497 0247_ $$2ISSN$$a0031-9155
000154497 0247_ $$2ISSN$$a1361-6560
000154497 0247_ $$2altmetric$$aaltmetric:79918346
000154497 037__ $$aDKFZ-2020-00819
000154497 041__ $$aeng
000154497 082__ $$a530
000154497 1001_ $$aHoffmans, Daan$$b0
000154497 245__ $$aAn end-to-end test for MR-guided online adaptive radiotherapy.
000154497 260__ $$aBristol$$bIOP Publ.$$c2020
000154497 3367_ $$2DRIVER$$aarticle
000154497 3367_ $$2DataCite$$aOutput Types/Journal article
000154497 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1597322742_12711
000154497 3367_ $$2BibTeX$$aARTICLE
000154497 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154497 3367_ $$00$$2EndNote$$aJournal Article
000154497 500__ $$aVolume 65, Issue 12, 21 June 2020, Article number 125012
000154497 520__ $$aIn the evolving field of adaptive MR guided radiotherapy, the need for dedicated procedures for acceptance and quality assurance is increasing. Research has been devoted to MR compatible dosimeters and phantoms, but to date no end-to-end test has been presented that covers an MRgRT workflow. Such an end-to-end test should comprise each step of the workflow and include all associated uncertainties. The purpose of this study was to investigate the usability of an anthropomorphic deformable and multimodal pelvis (ADAM-pelvis) phantom in combination with film dosimetry for end-to-end testing of an MRgRT adaptive workflow. The ADAM-pelvis phantom included surrogates for muscle tissue, adipose and bone, as well as deformable silicone organs mimicking a prostate patient. At the interfaces of the critical structures (bladder and rectum), small pieces of GafChromic EBT3 films were placed to measure delivered dose. Pre-treatment MR imaging of the phantom was used to delineate the prostate, rectum and bladder and to generate a treatment plan to deliver 2 Gy to the prostate. Electron density (ED) map from CT imaging was used for dose calculation after deformable image registration (DIR) to the pre-treatment MR scan. At each fraction, bladder- and rectum filling was varied and a new adapted plan was generated. Dose calculation was performed using both a DIR-based ED map and a CT-based ED map after acquisition of a new CT scan of the phantom at each fraction. Dose calculations were performed taking into account the magnetic field. A good agreement between measured and calculated dose was found using both, the CT-derived and the DIR-based ED map (2.0% and 2.8% dose difference, respectively). The gamma index pass-rate (3% / 2 mm) varied from 96.4% to 100%.The ADAM-pelvis phantom was suitable for end-to-end testing in MR-guided radiotherapy and a very good agreement with the calculated dose was achieved.
000154497 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000154497 588__ $$aDataset connected to CrossRef, PubMed,
000154497 7001_ $$0P:(DE-He78)5c8b2018cd142f209c828d91e37a3e1a$$aNiebuhr, Nina Isabell$$b1$$udkfz
000154497 7001_ $$aBohoudi, Omar$$b2
000154497 7001_ $$0P:(DE-He78)435853c50cec6666e13c237685053577$$aPfaffenberger, Asja$$b3$$udkfz
000154497 7001_ $$aPalacios, Miguel A$$b4
000154497 773__ $$0PERI:(DE-600)1473501-5$$a10.1088/1361-6560/ab8955$$n12$$pArticle number 125012$$tPhysics in medicine and biology$$v65$$x1361-6560$$y2020
000154497 909CO $$ooai:inrepo02.dkfz.de:154497$$pVDB
000154497 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5c8b2018cd142f209c828d91e37a3e1a$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000154497 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)435853c50cec6666e13c237685053577$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000154497 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000154497 9141_ $$y2020
000154497 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000154497 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium
000154497 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPHYS MED BIOL : 2017
000154497 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000154497 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154497 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000154497 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000154497 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000154497 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000154497 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000154497 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000154497 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000154497 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000154497 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000154497 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lE040 Med. Physik in der Strahlentherapie$$x0
000154497 980__ $$ajournal
000154497 980__ $$aVDB
000154497 980__ $$aI:(DE-He78)E040-20160331
000154497 980__ $$aUNRESTRICTED